Hepatoprotective and cardioprotective effects of empagliflozin in spontaneously hypertensive rats fed a high-fat diet.

Autor: Hojná S; Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic., Malínská H; Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic., Hüttl M; Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic., Vaňourková Z; Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic., Marková I; Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic., Miklánková D; Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic., Hrdlička J; Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic., Papoušek F; Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic., Neckář J; Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic; Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, Prague, Czech Republic., Kujal P; 3rd Faculty of Medicine, Charles University, Prague, Czech Republic., Behuliak M; Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic., Rauchová H; Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic., Kadlecová M; Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic., Sedmera D; 1st Faculty of Medicine, Charles University, Prague, Czech Republic., Neffeová K; Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic; 1st Faculty of Medicine, Charles University, Prague, Czech Republic., Zábrodská E; 1st Faculty of Medicine, Charles University, Prague, Czech Republic., Olejníčková V; 1st Faculty of Medicine, Charles University, Prague, Czech Republic., Zicha J; Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic., Vaněčková I; Institute of Physiology, Czech Academy of Sciences, Prague, Czech Republic. Electronic address: ivana.vaneckova@fgu.cas.cz.
Jazyk: angličtina
Zdroj: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 May; Vol. 174, pp. 116520. Date of Electronic Publication: 2024 Apr 05.
DOI: 10.1016/j.biopha.2024.116520
Abstrakt: A combination of liver and heart dysfunction worsens the prognosis of human survival. The aim of this study was to investigate whether empagliflozin (a sodium-glucose transporter-2 inhibitor) has beneficial effects not only on cardiac and renal function but also on hepatic function. Adult (6-month-old) male spontaneously hypertensive rats (SHR) were fed a high-fat diet (60% fat) for four months to induce hepatic steatosis and mild heart failure. For the last two months, the rats were treated with empagliflozin (empa, 10 mg.kg -1 .day -1 in the drinking water). Renal function and oral glucose tolerance test were analyzed in control (n=8), high-fat diet (SHR+HF, n=10), and empagliflozin-treated (SHR+HF+empa, n=9) SHR throughout the study. Metabolic parameters and echocardiography were evaluated at the end of the experiment. High-fat diet feeding increased body weight and visceral adiposity, liver triglyceride and cholesterol concentrations, and worsened glucose tolerance. Although the high-fat diet did not affect renal function, it significantly worsened cardiac function in a subset of SHR rats. Empagliflozin reduced body weight gain but not visceral fat deposition. It also improved glucose sensitivity and several metabolic parameters (plasma insulin, uric acid, and HDL cholesterol). In the liver, empagliflozin reduced ectopic lipid accumulation, lipoperoxidation, inflammation and pro-inflammatory HETEs, while increasing anti-inflammatory EETs. In addition, empagliflozin improved cardiac function (systolic, diastolic and pumping) independent of blood pressure. The results of our study suggest that hepatoprotection plays a decisive role in the beneficial effects of empagliflozin in preventing the progression of cardiac dysfunction induced by high-fat diet feeding.
Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest.
(Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: